SAN DIEGO, Sept. 7, 2016 /PRNewswire/ -- Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced that its chief executive officer, Brian Lian, Ph.D., will deliver corporate presentations at two upcoming investor conferences in New York, NY. Dr. Lian will present at the Rodman & Renshaw 18th Annual Global Investment Conference, being held September 11-13, 2016, and the Ladenburg Thalmann 2016 Healthcare Conference, being held on September 27, 2016.
Details of these presentations are as follows:
|
• |
Rodman & Renshaw 18th Annual Global Investment Conference | |
|
Time/Date: |
Tuesday, Sept. 13 at 12:05-12:30 PM ET | |
|
Location: |
The Lotte New York Palace Hotel, New York City | |
|
Room: |
Holmes II (4th Floor) | |
|
• |
Ladenburg Thalmann 2016 Healthcare Conference | |
|
Time/Date: |
Tuesday, Sept. 27 at 2:00-2:25 PM ET | |
|
Location: |
Sofitel New York, New York City | |
|
Room: |
Montmartre - Track 5 | |
To access the live webcast of Viking's presentations, please visit "Webcasts & Presentations" within the News & Events section of Viking's Investors page at www.vikingtherapeutics.com. Additionally, a replay of the webcasts will be available on the Viking website following the conference.
About Viking Therapeutics, Inc.
Viking Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on the development of novel, first-in-class or best-in-class therapies for metabolic and endocrine disorders. The company's research and development activities leverage its expertise in metabolism to develop innovative therapeutics designed to improve patients' lives. Viking has exclusive worldwide rights to a portfolio of five therapeutic programs in clinical trials or preclinical studies, which are based on small molecules licensed from Ligand Pharmaceuticals Incorporated. The company's clinical programs include VK5211, an orally available, non-steroidal selective androgen receptor modulator, or SARM, in Phase 2 development for the treatment and prevention of lean body mass loss in patients who have undergone hip fracture surgery, VK2809, a small molecule thyroid beta agonist entering Phase 2 development for hypercholesterolemia and fatty liver disease, and VK0612, a first-in-class, orally available drug candidate in Phase 2 development for type 2 diabetes. Viking is also developing novel and selective agonists of the thyroid beta receptor for adrenoleukodystrophy, as well as two earlier-stage programs targeting metabolic diseases and anemia.
Follow Viking on Twitter @Viking_VKTX.
SOURCE Viking Therapeutics, Inc